Critical Milestones Achieved Ahead of Schedule in Lung Cancer Study
Case Study
Feb 01, 2019
This case study summarizes how IQVIA Biotech helped a biotechnology company reach critical milestones as it prepared to launch an international Phase III clinical trial for its investigational anaplastic lymphoma kinase (ALK) inhibitor in patients with non-small cell lung cancer (NSCLC).
Contact Us
Contact Us

Email Us

Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward?

Call Us

We're available during standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.